Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Status unconfirmed · Phase 2

Conditions studied: Autoimmune Thrombocytopenic Purpura

In brief

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Key facts

Study ID

NCT00107913

Run by

Hematology and Oncology Specialists

People needed

10

Starts

2001-09-01

Expected to finish

2005-04-01

Last updated by the study team

2005-06-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Thrombocytopenia with bone marrow findings showing normal or increased numbers of megakaryocytes.
• Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy and post splenectomy steroids.
• Platelet count of 30,000 or less.
• Performance status score of 2 or less.
• Adequate organ function: *bilirubin< 2; *AST < 3 times normal; *creatinine < 2.
• No prior treatment with anthracycline or chemically related drugs.

You may not qualify if…

• Pregnant or lactating women.
• Presence of a malignancy other than basal cell carcinoma of the skin.

Where it is running

• Hematology and Oncology Specialists — Metairie, Louisiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.